Dr. Mosher is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1821 Hillandale Rd Unit 25
Durham, NC 27705Phone+1 919-620-7300
Education & Training
- Duke University HospitalFellowship, Pulmonary Disease and Critical Care Medicine, 2017 - 2021
- Indiana University School of MedicineResidency, Internal Medicine, 2014 - 2017
- Indiana University School of MedicineClass of 2014
Certifications & Licensure![](https://directory.doximity.com/assets/icons/icon-help-e9f0b148a1e6d1f037dde9f26f025c36bd7c99fd4fe31fd76792996fa2aa5e66.svg)
- NC State Medical License 2018 - 2025
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Pulmonary Disease
Publications & Presentations
PubMed
- Risk of Atherosclerotic Cardiovascular Disease After Chronic Obstructive Pulmonary Disease Hospitalization among Primary and Secondary Prevention Older Adults.Christopher L Mosher, Oyomoare L Osazuwa-Peters, Michael G Nanna, Neil R MacIntyre, Loretta G Que
Journal of the American Heart Association. 2025-01-21 - Feasibility, Usability, and Pilot Efficacy Study of a Software-Enabled, Virtual Pulmonary Rehabilitation with Remote Therapeutic Monitoring.Sheryl Flynn, Christopher L Mosher, Sharon Cornelison, Erica Rao, Kimberly A Metzler
International Journal of Chronic Obstructive Pulmonary Disease. 2025-01-01 - Risk of Atherosclerotic Cardiovascular Disease Hospitalizations after Chronic Obstructive Pulmonary Disease Hospitalization among Older Adults.Christopher L Mosher, Oyomoare L Osazuwa-Peters, Michael G Nanna, Neil R MacIntyre, Loretta G Que
Annals of the American Thoracic Society. 2024-11-01
Press Mentions
- Pulmonary Rehab After COPD Hospitalization Results in Net Cost SavingsJuly 15th, 2022
- FDA Approves New COPD Drug Developed by Firm in Raleigh. First New Treatment in a DecadeJuly 3rd, 2024
Professional Memberships
- Member
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: